• Citer

An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

par Bonnefoi, H;Biganzoli, Laura ;Mauriac, L;Cufer, T;Schaefer, P;Atalay, G;Piccart-Gebhart, Martine
Référence European journal of cancer, 39, 9, page (1277-1283)
Publication Publié, 2003-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Auteur:	Bonnefoi, H; Biganzoli, Laura; Mauriac, L; Cufer, T; Schaefer, P; Atalay, G; Piccart-Gebhart, Martine
Informations sur la publication:	European journal of cancer, 39, 9, page (1277-1283)
Statut de publication:	Publié, 2003-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adenocarcinoma -- drug therapy
	Adenocarcinoma -- pathology
	Adolescent
	Adult
	Aged
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- pathology
	Chemotherapy, Adjuvant
	Cyclophosphamide -- administration & dosage
	Cyclophosphamide -- adverse effects
	Deoxycytidine -- administration & dosage
	Deoxycytidine -- adverse effects
	Deoxycytidine -- analogs & derivatives
	Dose-Response Relationship, Drug
	Epirubicin -- administration & dosage
	Epirubicin -- adverse effects
	Female
	Fluorouracil -- analogs & derivatives
	Humans
	Middle Aged
	Patient Compliance
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase I
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:pii/S0959804903002661
	info:pmid/12763217